The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer

Pyrotinib (PYR) is a pan-HER kinase inhibitor that inhibits signaling via the RAS/RAF/MEK/MAPK and PI3K/AKT pathways. In this study, we aimed to investigate the antitumor efficacy of pyrotinib combined with adriamycin (ADM) and explore its mechanisms on HER2(+) breast cancer. We investigated the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chaokun, Deng, Shuzhen, Chen, Jing, Xu, Xiangyun, Hu, Xiaochen, Kong, Dejiu, Liang, Gaofeng, Yuan, Xiang, Li, Yuanpei, Wang, Xinshuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177085/
https://www.ncbi.nlm.nih.gov/pubmed/34094901
http://dx.doi.org/10.3389/fonc.2021.616443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177085/
https://www.ncbi.nlm.nih.gov/pubmed/34094901
http://dx.doi.org/10.3389/fonc.2021.616443

Ejemplares similares